Copy For Citation
Onal C., Kose F., Ozyigit G., Aksoy S., Oymak E., Muallaoglu S., ...More
The Prostate, vol.81, pp.543-552, 2021 (SCI-Expanded)
Article / Article
Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
abiraterone, enzalutamide, oligometastasis, prostate cancer, stereotactic radiotherapy, MITOXANTRONE PLUS PREDNISONE, ABIRATERONE ACETATE, INCREASED SURVIVAL, RADIATION-THERAPY, DOUBLE-BLIND, ENZALUTAMIDE, DOCETAXEL, PROGRESSION, CHEMOTHERAPY, DECLINE
Hacettepe University Affiliated:
Background Metastasis-directed therapy (MDT) utilizing stereotactic body radiotherapy (SBRT) for oligoprogressive lesions could provide a delay in next-line systemic treatment (NEST) change while undergoing androgen receptor-targeted agents (ARTA) treatment. We evaluated prognostic factors for prostate cancer-specific survival (PCSS) and progression-free survival (PFS) to characterize patients receiving treatment with ARTA who may benefit from MDT for oligoprogressive lesions. The impact of MDT on delaying NEST and the predictive factors for NEST-free survival (NEST-FS) were also assessed.